Cited 69 times in
The Val279Phe Variant of the Lipoprotein-Associated Phospholipase A2 Gene Is Associated with Catalytic Activities and Cardiovascular Disease in Korean Men
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고영국 | - |
dc.contributor.author | 장양수 | - |
dc.date.accessioned | 2015-06-10T12:58:23Z | - |
dc.date.available | 2015-06-10T12:58:23Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 0021-972X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/110780 | - |
dc.description.abstract | CONTEXT AND OBJECTIVE: It is unclear whether lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) exerts a pro- or antiatherogenic effect on cardiovascular disease (CVD). We investigated the association between Lp-PLA(2) variant (V279F and A379V) and CVD in Korean men. DESIGN: CVD patients (n = 532) and healthy controls (n = 670) were genotyped for the Lp-PLA(2) polymorphism (V279F and A379V). MAIN OUTCOME MEASURES: We calculated odds ratio (OR) on CVD risk and measured anthropometries, lipid profiles, low-density lipoprotein (LDL) particle size, oxidized LDL, lipid peroxides, and Lp-PLA(2) activity. RESULTS: The presence of the 279F allele was associated with a lower risk of CVD [OR 0.646 (95% confidence interval 0.490-0.850), P = 0.002], and the association still remained after adjustments for age, body mass index, waist circumference, waist to hip ratio, cigarette smoking, and alcohol consumption [OR 0.683 (95% confidence interval 0.512-0.911), P = 0.009]. Lp-PLA(2) activity was lower in CVD patients taking a lipid-lowering drug (31%), those not taking a lipid-lowering drug (26%), and control subjects (23%) with the V/F genotype, compared with those with the V/V genotype. Subjects with the F/F genotype in controls and two CVD patients groups showed no appreciable enzymatic activity. Control subjects with the V/F genotype had larger LDL particle size than those with the V/V genotype. In addition, control subjects carrying the F allele showed lower malondialdehyde concentrations. On the other hand, we found no significant relationship between A379V genotype and CVD risk. CONCLUSIONS: The association of the F279 loss of function variant with the reduced risk of CVD supports the concept that Lp-PLA(2) plays a proatherogenic and causative role in CVD. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 3521~3527 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | 1-Alkyl-2-acetylglycerophosphocholine Esterase | - |
dc.subject.MESH | Cardiovascular Diseases/enzymology* | - |
dc.subject.MESH | Cardiovascular Diseases/genetics | - |
dc.subject.MESH | Cardiovascular Diseases/metabolism | - |
dc.subject.MESH | Case-Control Studies | - |
dc.subject.MESH | Cholesterol/blood | - |
dc.subject.MESH | DNA/genetics | - |
dc.subject.MESH | Dinoprost/analogs & derivatives | - |
dc.subject.MESH | Dinoprost/urine | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Korea | - |
dc.subject.MESH | Lipoproteins, LDL/blood | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Malondialdehyde/blood | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Particle Size | - |
dc.subject.MESH | Phospholipases A/genetics* | - |
dc.subject.MESH | Phospholipases A/metabolism | - |
dc.subject.MESH | Phospholipases A2 | - |
dc.subject.MESH | Polymorphism, Single Nucleotide | - |
dc.subject.MESH | Triglycerides/blood | - |
dc.title | The Val279Phe Variant of the Lipoprotein-Associated Phospholipase A2 Gene Is Associated with Catalytic Activities and Cardiovascular Disease in Korean Men | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.contributor.googleauthor | Oh Yoen Kim | - |
dc.contributor.googleauthor | Soo Jeong Koh | - |
dc.contributor.googleauthor | Jey Sook Chae | - |
dc.contributor.googleauthor | Young Guk Ko | - |
dc.contributor.googleauthor | Ji Young Kim | - |
dc.contributor.googleauthor | Hongkeun Cho | - |
dc.contributor.googleauthor | Tae-Sook Jeong | - |
dc.contributor.googleauthor | Woo Song Lee | - |
dc.contributor.googleauthor | Jose M. Ordovas | - |
dc.contributor.googleauthor | Jong Ho Lee | - |
dc.identifier.doi | 10.1210/jc.2006-0116 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00127 | - |
dc.contributor.localId | A03448 | - |
dc.relation.journalcode | J01318 | - |
dc.identifier.eissn | 1945-7197 | - |
dc.identifier.pmid | 16787988 | - |
dc.identifier.url | http://press.endocrine.org/doi/abs/10.1210/jc.2006-0116?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed | - |
dc.contributor.alternativeName | Ko, Young Guk | - |
dc.contributor.alternativeName | Jang, Yang Soo | - |
dc.contributor.affiliatedAuthor | Ko, Young Guk | - |
dc.contributor.affiliatedAuthor | Jang, Yang Soo | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 91 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 3521 | - |
dc.citation.endPage | 3527 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, Vol.91(9) : 3521-3527, 2006 | - |
dc.identifier.rimsid | 54428 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.